InvestorsHub Logo
Followers 10
Posts 536
Boards Moderated 0
Alias Born 02/06/2019

Re: lesgetrich post# 1287

Monday, 11/18/2019 9:20:05 AM

Monday, November 18, 2019 9:20:05 AM

Post# of 1346
rmata's ability to advance its preclinical and clinical programs and the uncertain and time-consuming regulatory approval process

Yep, necessary, yet inflexible to allow those with a lot more clear cut results than others to advance faster and get their treatment to those needing as soon as practical rather than following a hard timeline.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ARMP News